Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis

World Journal of Gastroenterology

Volumn 23, Issue 13, 2017, Pages 2396-2403

  Lee, Soon Kyu ^a   Song, Myeong Jun ^a   Kim, Seok Hyun ^b   Lee, Byung Seok ^b   Lee, Tae Hee ^c   Kang, Young Woo ^c   Kim, Suk Bae ^d   Song, Il Han ^d   Chae, Hee Bok ^e   Ko, Soon Young ^f   Lee, Jae Dong ^f  

^a Daejeon St Mary's Hospital   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

^c Konyang University College of Medicine   (South Korea)

^d Dankook University   (South Korea)

^e Chungbuk University Hospital   (South Korea)

^f Konkuk University Hospital   (South Korea)

Author keywords

Compensated liver cirrhosis; Decompensated liver cirrhosis; Renal safety; Tenofovir; Virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD PUGH SCORE; CHRONIC HEPATITIS B; COMPLETE VIROLOGICAL RESPONSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; SEROCONVERSION; SIDE EFFECT; SOUTH KOREAN; TREATMENT OUTCOME; COMPLICATION; LIVER CIRRHOSIS; MIDDLE AGED; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TENOFOVIR;

EID: 85017162704     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i13.2396     Document Type: Article

References (15)

1. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 47-58 [PMID: 12616450 DOI: 10. 1055/ s-2003-37590]
2. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352 [PMID: 18096267 DOI: 10. 1016/j. jhep. 2007. 11. 011]
3. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10. 1016/j. jhep. 2012. 02. 010]
4. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-283 [PMID: 26566064 DOI: 10. 1002/ hep. 28156]
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10. 1002/hep. 24199]
6. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182 [PMID: 20006394 DOI: 10. 1016/j. jhep. 2009. 11. 007]
7. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72 [PMID: 21254162 DOI: 10. 1002/hep. 23952]
8. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537-1547 [PMID: 23389810 DOI: 10. 1002/hep. 26301]
9. Köklü S, Tuna Y, Gülen MT, Demir M, Köksal A, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibi M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Baar O, Alkan E, Baykal O. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013; 11: 88-94 [PMID: 23063679 DOI: 10. 1016/ j. cgh. 2012. 10. 003]
10. Miquel M, Núñez Ó, Trapero-Marugán M, Díaz-Sánchez A, Jiménez M, Arenas J, Canós AP. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol 2013; 12: 205-212 [PMID: 23396731]
11. Cholongitas E, Papatheodoridis GV, Goulis J, Vlachogiannakos J, Karatapanis S, Ketikoglou J, Vasiliadis T, Kontos G, Karlaftis A, Akriviadis E. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Ann Gastroenterol 2015; 28: 109-117 [PMID: 25608681]
12. Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect 2016; 22: 95. e1-95. e7 [PMID: 26055419 DOI: 10. 1016/j. cmi. 2015. 05. 035]
13. Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int 2016; 36 Suppl 1: 85-92 [PMID: 26725903 DOI: 10. 1111/liv. 13003]
14. Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther 2014; 19: 687-692 [PMID: 24699134 DOI: 10. 3851/imp2770]
15. Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, McHutchison JG, Gane EJ, Foster GR. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 2015; 62: 533-540 [PMID: 25450717 DOI: 10. 1016/j. jhep. 2014. 10. 035]